Page 12 of 178: studies 111 to 120 of 1,772, newest first. Back to the neuroplasticity overview
Journal of Addiction & Addictive Disorders July 17, 2023 Kargbo Rb
The expanding field of psychedelic-assisted therapy presents innovative treatment avenues for various mental health disorders. This review explores the potential role of psychedelics in enhancing neuroplasticity, a key mechanism underlying recovery from mental health conditions.
British Journal of Pharmacology July 13, 2023 Sabrine Bilel, Erica Zamberletti, Lucia Caffino et al.
Background and purpose: Psychotic disorders have been reported in long-term users of synthetic cannabinoids. This study aims at investigating the long-lasting effects of repeated JWH-018 exposure. Experimental approach: Male CD-1 mice were injected with vehicle, JWH-018 (6 mg·kg-1 ), the CB1 -antagonist NESS-0327 (1 mg·kg-1 ) or co-administration of NESS-0327 and JWH-018, every day for 7 days....
BMC Neuroscience June 30, 2023 Rachael Sumner, Kacper Łukasiewicz 6 citations
When it comes to studying neural plasticity and psychedelics, the numerous and diverse neuroscientific fields converging on the topic provide unique insight into a complex picture. This editorial will describe the major ways in which the known effects of psychedelics on plasticity are being studied. We lay out strengths of different techniques and the major gaps and room for future research,...
Journal of Psychopharmacology June 30, 2023 Jordan Sloshower, Hamideh Safi-Aghdam, Surbhi Pathania et al. 47 citations
Background: Evidence suggests that serotonergic psychedelics (e.g. psilocybin), have rapid-acting and long-lasting antidepressant effects after a single dose. However, the mechanism underlying these effects remain unclear. One proposed mechanism is that these drugs promote neuroplasticity. However, this has not been conclusively demonstrated in humans. Aims: We hypothesized that relative to...
Translational Psychiatry May 9, 2023 Jared M. Kopelman, T. Keller, Benjamin Panny et al. 57 citations
Intravenous ketamine is posited to rapidly reverse depression by rapidly enhancing neuroplasticity. In human patients, we quantified gray matter microstructural changes on a rapid (24-h) timescale within key regions where neuroplasticity enhancements post-ketamine have been implicated in animal models. In this study, 98 unipolar depressed adults who failed at least one antidepressant medication...
Journal of Psychopharmacology March 1, 2023 Takesha Cooper, Michael David Seigler, Stephen M Stahl 18 citations
Numerous new agents with rapid onset antidepressant effects are entering clinical trials and clinical practice. Studies focus on either first-line treatment of major depressive disorder or on patients whose major depressive disorder is resistant to prior antidepressant drugs. Novel agents target three very different central nervous system sites: as antagonists of N-methyl-d-aspartate (NMDA)...
Pharmaceutics February 17, 2023 Valentina Castelli, Gianluca Lavanco, Salvatore Feo et al.
Previous evidence suggests that prenatal exposure to THC (pTHC) derails the neurodevelopmental trajectories towards a vulnerable phenotype for impaired emotional regulation and limbic memory. Here we aimed to investigate pTHC effect on hippocampus-related cognitive functions and markers of neuroplasticity in adolescent male offspring. Wistar rats were exposed to THC (2 mg/kg) from gestational...
Science February 16, 2023 Maxemiliano V. Vargas, Lee E. Dunlap, Chunyang Dong et al. 467 citations
Decreased dendritic spine density in the cortex is a hallmark of several neuropsychiatric diseases, and the ability to promote cortical neuron growth has been hypothesized to underlie the rapid and sustained therapeutic effects of psychedelics. Activation of 5-hydroxytryptamine (serotonin) 2A receptors (5-HT2ARs) is essential for psychedelic-induced cortical plasticity, but it is currently...
Frontiers in Neuroscience February 9, 2023 Lin-Chien Lee, Ya-Yun Chen, Wei-Chi Li et al.
Introduction Primary dysmenorrhea (PDM), the most prevalent gynecological problem among women of reproductive age, presents as a regular pattern of cyclic menstrual pain. The presence or absence of central sensitization (i.e., pain hypersensitivity) in cases of PDM is a contentious issue. Among Caucasians, the presence of dysmenorrhea is associated with pain hypersensitivity throughout the...
ACS Medicinal Chemistry Letters January 18, 2023 Robert B. Kargbo 2 citations
The renaissance of research into psychedelics class of drugs has renewed interest for a possible psychedelic clinical therapy for treating psychiatric conditions such as treatment-resistant depression, major depressive-disorder, post-traumatic stress disorder, and other neuropsychiatric diseases. Psychedelics are known to stimulate neurogenesis and gliogenesis, reduce inflammation, and...